Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results

Phase 3Negative

AI Analysis

Summary

Olema Pharmaceuticals shares declined 15.1% following AstraZeneca's SERENA-4 trial results announcement. The specific trial outcomes and drug details are not provided in the article excerpt.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

-0.80

Phase 3 trialSERENA-4stock declineAstraZeneca partnership

Related Companies

$AZN

Read the original article

Published by yahoo_finance on September 14, 2026 12:10 PM

Read Original